Close

Zynerba Pharma (ZYNE) Reports Positive Top Line Results from ZYN002 CBD Gel Phase 1, Plans Phase 2 Study

June 27, 2016 4:07 PM EDT Send to a Friend
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login